Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor ...

Most noteworthy is the danger of eating charred or burnt food, which contain toxic compounds that can raise the chances of developing prostate, bowel and ultra-lethal pancreatic cancer.

Carcinoid syndrome is a rare condition typically affecting ... Some patients with medullary thyroid cancers, pancreatic neuroendocrine tumors, and endogenous Cushing syndrome can also develop flushing ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Pancreatitis is inflammation of the pancreas. Acute pancreatitis occurs when symptoms appear suddenly. These may include pain in the upper left abdomen that spreads to the back, fever, nausea ...

The approval follows promising late-stage trial results showing that Cabometyx (cabozantinib) is effective in treating adults and children (12+) with previously treated, advanced pancreatic and ...

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...